2,029 results on '"Technetium Tc 99m Pyrophosphate"'
Search Results
2. Bronx Transthyretin Amyloid Cardiomyopathy Database
- Published
- 2024
3. A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
- Author
-
Attralus, Inc.
- Published
- 2023
4. Wild-Type Transthyretin Amyloidosis With 99mTc-PYP Uptake in the Extracardiac Soft Tissues But Not in the Myocardium.
- Author
-
Takahashi K, Iwamura T, Sasaki D, Ueda M, and Okura T
- Subjects
- Humans, Male, Radionuclide Imaging, Aged, Technetium Tc 99m Pyrophosphate, Female, Biological Transport, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial metabolism, Myocardium metabolism, Myocardium pathology
- Abstract
Abstract: Wild-type transthyretin amyloid (ATTRwt) deposits in most organs, mainly the heart, ligaments, and tenosynovium. Orthopedic diseases due to ATTRwt deposits often precede overt ATTRwt cardiomyopathy. 99mTc-PYP scintigraphy is highly sensitive in detecting myocardial and extracardiac ATTRwt deposits. However, there are few reports of extracardiac ATTRwt deposits before myocardial deposits confirmed by imaging modalities. We report a case of atrial fibrillation-related heart failure in which 99mTc-PYP scintigraphy showed tracer uptake in extracardiac soft tissues but not in the myocardium, and a biopsy of soft tissues with tracer uptake confirmed ATTRwt deposits. 99mTc-PYP scintigraphy can image extracardiac ATTRwt deposits before myocardial deposits., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Hot Hearts on Bone Scintigraphy Are Not All Amyloidosis: Hyperoxaluria-Associated Cardiomyopathy.
- Author
-
Wang YW, Xie YT, and Sun XX
- Subjects
- Humans, Female, Middle Aged, Bone and Bones diagnostic imaging, Technetium Tc 99m Pyrophosphate, Hyperoxaluria diagnostic imaging, Hyperoxaluria complications, Diagnosis, Differential, Cardiomyopathies diagnostic imaging, Radionuclide Imaging, Amyloidosis diagnostic imaging, Amyloidosis complications
- Abstract
Abstract: A 54-year-old woman with a history of end-stage renal disease was found to have infiltrative cardiomyopathy by echocardiography. 99m Tc-pyrophosphate ( 99m Tc-PYP) scintigraphy was positive with a remarkable myocardial uptake. Gene test found a mutation of AGXT , confirming a final diagnosis of primary hyperoxaluria. Radiotracer uptake was due to high myocardial oxalate deposition. This case illustrates false positivity of the 99m Tc-PYP scan caused by hyperoxaluria-associated cardiomyopathy, which raises awareness for other conditions apart from amyloid cardiomyopathy., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Extensive Pulmonary AL Amyloidosis Mimicking Miliary Tuberculosis: The Diagnostic Utility of 99m Tc-PYP Scintigraphy.
- Author
-
Denizmen D, Isik EG, Vuralli Bakkaloglu D, Buyukkaya F, and Sanli Y
- Subjects
- Humans, Diagnosis, Differential, Male, Middle Aged, Female, Aged, Lung Diseases diagnostic imaging, Amyloidosis diagnostic imaging, Immunoglobulin Light-chain Amyloidosis diagnostic imaging, Technetium Tc 99m Pyrophosphate, Tuberculosis, Miliary diagnostic imaging, Radionuclide Imaging
- Abstract
Abstract: Amyloidosis is a misfolded protein deposition disorder within the extracellular matrix, leading to dysfunction in the affected organ. Primary amyloidosis manifests as AL and ATTR subtypes, wherein AL is associated with plasma cell dyscrasias. Herein we present a case of a patient who underwent investigation due to the presence of bilateral reticulonodular lung infiltrates, suggestive of miliary tuberculosis. 99m Tc-PYP scan revealed widespread radiotracer uptake in the lungs leading to diagnosis of AL amyloidosis., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. A multicenter study of clinical predictors of positive pyrophosphate scintigraphy findings in the diagnosis of transthyretin amyloidosis.
- Author
-
Shingu M, Fujimoto W, Onishi T, Kuragaichi T, Murai R, Matsuo K, Inoue T, Takaya T, Matsumoto K, Matsue Y, Okuda M, and Tanaka H
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Predictive Value of Tests, Aged, 80 and over, Japan epidemiology, Radiopharmaceuticals, Retrospective Studies, Radionuclide Imaging methods, Cardiomyopathies diagnostic imaging, Amyloid Neuropathies, Familial diagnostic imaging, Technetium Tc 99m Pyrophosphate
- Abstract
Background: The prevalence of wild-type transthyretin (ATTR) amyloidosis is increasing with advancements in diagnostic techniques and growing awareness of the disease worldwide.
99m Tc-labeled pyrophosphate (99m Tc-PYP) scintigraphy exhibits high performance in diagnosing ATTR cardiac amyloidosis. This study aimed to validate the characteristics of patients with positive99m Tc-PYP scintigraphy results in a multicenter setting to provide more accurate case selection criteria., Methods and Results: In total, 180 patients with suspected ATTR amyloidosis underwent99m Tc-PYP scintigraphy in participating institutions in Japan between January 2018 and July 2022. Of 135 patients included in the analysis, 62 were99m Tc-PYP-positive. Logistic regression analysis was performed, and the following five factors were adopted to create a scoring system, with each weighted according to its odds ratio value; 1 point was scored for the absence of hypertension, existence of peripheral entrapment neuropathy (carpal tunnel syndrome or spinal canal stenosis), conduction disturbance (the presence of QRS complex ≥120 ms, first-degree atrioventricular block, higher degree of atrioventricular block, or presence of pacemaker implantation), and left ventricular hypertrophy and 2 points for troponin I/T ≥ 0.06 ng/mL.99m Tc-PYP scintigraphy positivity rate in the 0-point group was 0 %, whereas that in the 6-point group was 100 %. The area under the curve of the criteria was 0.820 (95 % confidence interval, 0.752-0.888; P < 0.001)., Conclusions: The combination of clinical information, which is easily available in local clinics, can provide accurate pretest prediction of positive99m Tc-PYP scintigraphy results. This will help clinicians to make an early diagnosis of ATTR amyloidosis., Competing Interests: Declaration of competing interest Yuya Matsue received an honorarium from Otsuka Pharmaceutical Co., Novartis Pharma K.K., Bayer Inc., and AstraZeneca, and a collaborative research grant from Pfizer Japan Inc., Otsuka Pharmaceutical Co., EN Otsuka Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd. Hidekazu Tanaka received remuneration from AstraZeneca plc, Ono Pharmaceutical Company, Limited. Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Abbott Japan LLC, and Novartis International AG., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2025
- Full Text
- View/download PDF
8. Quantitative 99m Tc-pyrophosphate myocardial uptake: Changes on transthyretin stabilization therapy.
- Author
-
Vijayakumar S, Pabon AR, Clerc OF, Cuddy SAM, Gu Y, Watts C, Sullivan K, Auer B, Kijewski MF, DiCarli MF, Falk RH, and Dorbala S
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Longitudinal Studies, Prospective Studies, Radiopharmaceuticals pharmacokinetics, Prealbumin metabolism, Cardiomyopathies diagnostic imaging, Cardiomyopathies metabolism, Myocardium metabolism, Aged, 80 and over, Amyloid Neuropathies, Familial diagnostic imaging, Technetium Tc 99m Pyrophosphate, Single Photon Emission Computed Tomography Computed Tomography methods
- Abstract
Background: Quantitative technetium-99m-pyrophosphate cardiac single-photon emission computed tomography (
99m Tc-PYP SPECT/CT) is an emerging method for estimating myocardial burden of transthyretin cardiac amyloidosis (ATTR-CA), but its efficacy in monitoring longitudinal changes remains uncertain. We aimed to investigate longitudinal changes in cardiac ATTR amyloid burden following transthyretin stabilization therapy using visual and quantitative99m Tc-PYP SPECT/CT and to relate these with changes in cardiac biomarkers and function., Methods: This prospective longitudinal cohort study investigated changes in99m Tc-PYP SPECT/CT in 23 participants with ATTR-CA on transthyretin stabilization therapy (median: 2.6 years). Quantitative analysis included left ventricular (LV) standardized uptake values (SUVs) (SUVmax , SUVmean ), cardiac amyloid activity (CAA; SUVmean ∗LV activity volume), and percent injected dose (%ID) (mean activity concentration∗LV activity volume/injected activity), calculated using a threshold of >1.5 times left atrial blood pool activity concentration on SPECT/CT. Longitudinal changes of paired continuous and ordinal variables were analyzed using Wilcoxon signed-rank test., Results: Following therapy, visual grade decreased significantly (P = 0.003). Several quantitative99m Tc-PYP metrics also decreased significantly: SUVmax (median -0.75, P = 0.011), CAA (median: -406.6, P < 0.001), and %ID (median: -0.45, P < 0.001). Serum transthyretin levels improved (median: +6.5 mg/dL, P = 0.008). Echocardiographic parameters (global longitudinal strain, LV mass index, and LV wall thickness), N-terminal pro-B-type natriuretic peptide, and estimated glomerular filtration rate remained stable., Conclusions: Favorable changes in99m Tc-PYP myocardial uptake were observed in participants on transthyretin stabilization therapy, whereas echocardiographic parameters and biomarkers remained stable. These results likely signify myocardial ATTR amyloid stabilization rather than amyloid burden regression. Further investigation is needed to understand the implications of these findings., (Copyright © 2024 American Society of Nuclear Cardiology. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
9. Detecting Amyloid Goiter With 99mTc-PYP SPECT/CT in the Setting of Ankylosing Spondylitis: An Uncommon Involvement of AA Amyloidosis.
- Author
-
Denizmen D, Salmaslioglu A, Bakkaloglu DV, Simsek DH, and Sanli Y
- Subjects
- Humans, Male, Technetium Tc 99m Pyrophosphate, Middle Aged, Amyloidosis diagnostic imaging, Amyloidosis complications, Spondylitis, Ankylosing diagnostic imaging, Spondylitis, Ankylosing complications, Single Photon Emission Computed Tomography Computed Tomography, Goiter diagnostic imaging, Goiter complications
- Abstract
Abstract: We present a case with systemic amyloidosis secondary to ankylosing spondylitis (AA amyloidosis), whose 99mTc PYP scintigraphy revealed amyloid deposition in the thyroid gland (amyloid goiter). Amyloidosis is characterized by extracellular accumulation of amyloid fibril proteins leading to organ malfunction. Even though AA amyloidosis can be observed in patients with systemic inflammatory diseases, it is a very rare complication in ankylosing spondylitis. SPECT/CT images showed diffuse tracer uptake in enlarged thyroid gland containing fat density areas., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. "Loss of Bone Signal" on 99m Tc-Labeled Pyrophosphate Scintigraphy in a Patient With Wild-Type Transthyretin Amyloidosis.
- Author
-
Takahashi K, Sasaki D, Iwamura T, Sakaue T, and Okura T
- Subjects
- Humans, Female, Aged, 80 and over, Prealbumin metabolism, Technetium Tc 99m Pyrophosphate, Radionuclide Imaging, Amyloid Neuropathies, Familial diagnostic imaging, Bone and Bones diagnostic imaging
- Abstract
Abstract: 99m Tc-3,3-diphosphono-1,2-propanedicarboxylic acid (DPD) scintigraphy and 99m Tc-pyrophosphate (PYP) scintigraphy are highly sensitive modalities for imaging both myocardial and extracardiac amyloid transthyretin in patients with wild-type transthyretin (ATTRwt) amyloidosis. "Loss of bone signal" on planar imaging of 99m Tc-DPD scintigraphy, in which the tracer uptake in bone is obscured by marked tracer uptake in the overlying skeletal muscles, is reported. However, this phenomenon has not yet been documented on 99m Tc-PYP scintigraphy. We describe an 89-year-old woman with ATTRwt amyloidosis in whom "loss of bone signal" together with marked tracer uptake into the skeletal muscles was clearly demonstrated on 99m Tc-PYP scan., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Bilateral Multiple Fractures Obstruct Quantitation of 99m Tc-Pyrophosphate Imaging for Cardiac Amyloidosis.
- Author
-
Zhou Q, Zuo J, Xiao L, Jiang L, and Zhao Z
- Subjects
- Humans, Female, Middle Aged, Single Photon Emission Computed Tomography Computed Tomography, Amyloid Neuropathies, Familial diagnostic imaging, Amyloidosis diagnostic imaging, Cardiomyopathies diagnostic imaging, Fractures, Bone diagnostic imaging, Technetium Tc 99m Pyrophosphate
- Abstract
Abstract: A 57-year-old woman who had persistent symptoms of transthyretin cardiac amyloidosis underwent 99m Tc-pyrophosphate ( 99m Tc-PYP) scintigraphy. The 99m Tc-PYP planar and SPECT/CT fusion image showed diffuse myocardial uptake and multiple fractures of the sternum and ribs. These fractures interfered with semiquantitative scores of 99m Tc-PYP uptake, leading to false positive in 99m Tc-PYP imaging., Competing Interests: Conflicts of interest and sources of funding: The current study was supported by the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYGD23016&2021HXFH033), and Quantitative parameters of 99m Tc-PYP SPECT/CT in the Diagnosis of Myocardial Amyloidosis (CGY2023-122)., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Deep Learning-Enabled Quantification of 99m Tc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis.
- Author
-
Miller RJH, Shanbhag A, Michalowska AM, Kavanagh P, Liang JX, Builoff V, Fine NM, Dey D, Berman DS, and Slomka PJ
- Subjects
- Humans, Female, Male, Aged, Aged, 80 and over, Cardiomyopathies diagnostic imaging, Image Processing, Computer-Assisted, Amyloid Neuropathies, Familial diagnostic imaging, Middle Aged, Amyloidosis diagnostic imaging, Technetium Tc 99m Pyrophosphate, Deep Learning, Single Photon Emission Computed Tomography Computed Tomography
- Abstract
Transthyretin cardiac amyloidosis (ATTR CA) is increasingly recognized as a cause of heart failure in older patients, with
99m Tc-pyrophosphate imaging frequently used to establish the diagnosis. Visual interpretation of SPECT images is the gold standard for interpretation but is inherently subjective. Manual quantitation of SPECT myocardial99m Tc-pyrophosphate activity is time-consuming and not performed clinically. We evaluated a deep learning approach for fully automated volumetric quantitation of99m Tc-pyrophosphate using segmentation of coregistered anatomic structures from CT attenuation maps. Methods: Patients who underwent SPECT/CT99m Tc-pyrophosphate imaging for suspected ATTR CA were included. Diagnosis of ATTR CA was determined using standard criteria. Cardiac chambers and myocardium were segmented from CT attenuation maps using a foundational deep learning model and then applied to attenuation-corrected SPECT images to quantify radiotracer activity. We evaluated the diagnostic accuracy of target-to-background ratio (TBR), cardiac pyrophosphate activity (CPA), and volume of involvement (VOI) using the area under the receiver operating characteristic curve (AUC). We then evaluated associations with the composite outcome of cardiovascular death or heart failure hospitalization. Results: In total, 299 patients were included (median age, 76 y), with ATTR CA diagnosed in 83 (27.8%) patients. CPA (AUC, 0.989; 95% CI, 0.974-1.00) and VOI (AUC, 0.988; 95% CI, 0.973-1.00) had the highest prediction performance for ATTR CA. The next highest AUC was for TBR (AUC, 0.979; 95% CI, 0.964-0.995). The AUC for CPA was significantly higher than that for heart-to-contralateral ratio (AUC, 0.975; 95% CI, 0.952-0.998; P = 0.046). Twenty-three patients with ATTR CA experienced cardiovascular death or heart failure hospitalization. All methods for establishing TBR, CPA, and VOI were associated with an increased risk of events after adjustment for age, with hazard ratios ranging from 1.41 to 1.84 per SD increase. Conclusion: Deep learning segmentation of coregistered CT attenuation maps is not affected by the pattern of radiotracer uptake and allows for fully automatic quantification of hot-spot SPECT imaging such as99m Tc-pyrophosphate. This approach can be used to accurately identify patients with ATTR CA and may play a role in risk prediction., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
13. Conversion of PYP/HMDP scanning on sequential imaging in a patient with a TTR gene mutation.
- Author
-
Hansen CL, Farber J, Binder A, Reist K, and Brailovsky Y
- Subjects
- Humans, Male, Radiopharmaceuticals, Technetium Tc 99m Pyrophosphate, Technetium Tc 99m Medronate, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial genetics, Middle Aged, Female, Mutation, Prealbumin genetics
- Published
- 2024
- Full Text
- View/download PDF
14. Utilising pyrophosphate uptake imaging to establish the timing of acute myocardial infarction: An often-forgotten art.
- Author
-
Russo JJ, Liu B, Lefkovits J, and Better N
- Subjects
- Humans, Male, Aged, Radiopharmaceuticals, Myocardial Infarction, Technetium Tc 99m Pyrophosphate
- Abstract
Introduction: While pyrophosphate uptake imaging with Technetium-99 m pyrophosphate (Tc-99 m PYP) is frequently used for cardiac ATTR amyloid imaging, its role in determining the timing of acute myocardial infarction (AMI) is near forgotten. We present a case that demonstrates the clinical benefit of pyrophosphate uptake imaging in differentiating recent from remote infarction as a reminder of the continued utility of pyrophosphate uptake imaging for this indication., Case and Outcomes: A 68-year-old male was referred for surgical replacement of his bicuspid aortic valve with severe aortic regurgitation. He was clinically well, but an elective pre-operative electrocardiogram suggested an anteroseptal wall infarct of possibly recent onset. Troponin-I was elevated at 430 ng/L (N < 26 ng/L) but did not change significantly over several days. Coronary angiography confirmed an occluded left anterior descending artery. Tc-99 m PYP uptake imaging was then utilised to determine the age of infarct and demonstrated mild regional tracer uptake in the left ventricular apex, consistent with a recent infarction. As the infarct was recent, elective surgery was postponed., Discussion: In this case, the age of the patient's AMI had an important bearing on the timing of his elective surgical aortic valve replacement. Given the recommendation to delay elective cardiac surgery in patients with recent myocardial infarction to reduce peri‑operative morbidity and mortality, this now rare use of pyrophosphate uptake imaging was critical in helping determine when cardiac surgery could be performed safely., Conclusion: This case demonstrates the clinical utility of pyrophosphate uptake imaging in establishing the temporal profile of myocardial infarction to help guide appropriate clinical management., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
15. A Gluteus Medius Muscle Biopsy to Confirm Amyloid Transthyretin Deposition in Wild-type Transthyretin Cardiac Amyloidosis: A Report of Two Cases.
- Author
-
Takahashi K, Iwamura T, Hiratsuka Y, Sasaki D, Yamamura N, Ueda M, Morioka H, Yoshino M, Enomoto D, Uemura S, Okura T, Sakaue T, and Ikeda S
- Subjects
- Humans, Biopsy, Buttocks pathology, Buttocks diagnostic imaging, Cardiomyopathies pathology, Cardiomyopathies diagnostic imaging, Cardiomyopathies metabolism, Cardiomyopathies diagnosis, Radiopharmaceuticals, Technetium Tc 99m Pyrophosphate, Tomography, X-Ray Computed, Amyloid Neuropathies, Familial pathology, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial metabolism, Muscle, Skeletal pathology, Muscle, Skeletal diagnostic imaging, Muscle, Skeletal metabolism, Prealbumin genetics, Prealbumin metabolism
- Abstract
In patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), the uptake of the tracer on technetium-99m-labeled pyrophosphate (
99m Tc-PYP) scintigraphy, which indicates amyloid transthyretin (ATTR) per se, is often observed in skeletal muscles, such as the abdominal oblique and gluteal muscles. Among extracardiac biopsies for confirming ATTR deposition in ATTRwt-CA, a99m Tc-PYP imaging-based computed tomography (CT)-guided core needle biopsy of the internal oblique muscle has relatively high sensitivity. In some patients, the99m Tc-PYP uptake is more pronounced in the gluteal muscles than in oblique muscles. We herein report two cases of ATTRwt-CA in which a CT-guided biopsy of the gluteus medius muscle with99m Tc-PYP uptake confirmed the presence of ATTR deposits.- Published
- 2024
- Full Text
- View/download PDF
16. The Most Predictive Red Flags for Suspecting Cardiac Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction.
- Author
-
Yalvaç HE, Murat S, Ak Sivrikoz İ, Üsküdar Teke H, Çilingir O, Çolak E, and Çavuşoğlu Y
- Subjects
- Radionuclide Imaging, Prospective Studies, Humans, Male, Female, Middle Aged, Aged, Age Factors, Technetium Tc 99m Pyrophosphate, Heart Failure, Diastolic diagnosis, Heart Failure, Diastolic etiology, Heart Failure, Diastolic physiopathology, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial physiopathology
- Abstract
Objective: Cardiac amyloidosis (CA) is a cardiomyopathy characterized by amyloid infiltration in the myocardium. Transthyretin cardiac amyloidosis (TTR-CA), commonly presenting as heart failure with preserved ejection fraction (HFpEF), was the focus of our study, which aimed to identify red flags that heighten suspicion of CA in HFpEF patients., Methods: We prospectively included patients diagnosed with HFpEF. All patients were assessed for TTR-CA red flag features, cardiac and extra-cardiac, as outlined in the 'Diagnosis and Treatment of Cardiac Amyloidosis: A Position Statement of the European Society of Cardiology.' Technetium-99m pyrophosphate (99mTc-PYP) cardiac scintigraphy was performed in 167 HFpEF patients suspected of having TTR-CA. Patients testing positive and negative for TTR-CA were compared based on these red flag features., Results: Out of 167 HFpEF patients, 19 (11.3%) were diagnosed with TTR-CA. In the TTR-CA group, 17 (89.5%) patients were 65 years or older. The presence of three or more red flags differentiated the TTR-CA positive and negative groups (P = 0.040). Features such as low voltage and pseudo infarct patterns were more prevalent in the TTR-CA group (P < 0.001 and P < 0.048, respectively). Left ventricular global longitudinal strain (LV-GLS) was lower in the TTR-CA positive group (P < 0.001). Multivariate analysis identified four variables-older age, pseudo infarct pattern, low/decreased QRS voltage, and LV-GLS-as strong, independent predictors of TTR-CA, with significant odds ratios (ORs) of 7.8, 6.8, 16.9, and 1.2, respectively., Conclusion: In this study, TTR-CA etiology occurs in approximately one in every ten HFpEF patients. The presence of three or more red flags increases the likelihood of TTR-CA. Older age, pseudo infarct pattern, low/decreased QRS voltage, and reduced LV-GLS are the most significant red flags indicating TTR-CA in HFpEF patients.
- Published
- 2024
- Full Text
- View/download PDF
17. Vicarious excretion of 99m Tc-pyrophosphate in the gallbladder.
- Author
-
Kavanaugh M and Shah HJ
- Subjects
- Humans, Male, Female, Aged, Amyloidosis diagnostic imaging, Middle Aged, Cardiomyopathies diagnostic imaging, Technetium Tc 99m Pyrophosphate, Gallbladder diagnostic imaging, Radiopharmaceuticals pharmacokinetics
- Abstract
Vicarious excretion of tracer and contrast media is a known phenomenon and is not fully understood [1,2]. We report a case of unexpected vicarious excretion of
99m Tc-pyrophosphate in the gallbladder seen on a scan performed to evaluate suspected cardiac amyloidosis, which is the first report of this phenomenon to the best of our knowledge., (Copyright © 2024 American Society of Nuclear Cardiology. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
18. Performance of 99m Tc-PYP scintigraphy in the diagnosis of hereditary transthyretin cardiac amyloidosis.
- Author
-
Guo H, Wu S, Xiang X, Wang S, Fang Z, Ye Q, Zou Y, Wang Y, Peng D, and Ma X
- Subjects
- Humans, Technetium Tc 99m Pyrophosphate, Prealbumin genetics, Heart, Radionuclide Imaging, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial genetics, Cardiomyopathies diagnostic imaging
- Abstract
Objective: Most reported research has primarily investigated wild-type transthyretin cardiac amyloidosis (ATTRwt-CA). However, the application of bone scintigraphy for hereditary transthyretin cardiac amyloidosis (ATTRv-CA) has not been systematically investigated. Therefore, in this study, we aimed to evaluate the diagnostic value of
99m Tc-PYP scintigraphy in ATTRv-CA., Methods: Fifty-four patients were enrolled in a highly suspected cardiac amyloidosis cohort. Transthyretin (TTR) gene characteristics were summarized in the ATTRv-CA group. In99m Tc-PYP scintigraphy, the diagnostic efficiency of the visual score (VGS) and heart-to-contralateral chest (H/CL) ratio were evaluated. Furthermore, the interobserver consistency among the diagnosticians was investigated., Results: Twenty-eight patients were diagnosed with ATTRv-CA with eight genotypes. The Ala97Ser genotype accounts for 46% (n = 13) with a mean age of disease onset, definite diagnosis, and interval of 61.6 ± 1.9, 66.5 ± 1.3, and 4.0 (3.0, 6.2) years, respectively. Their VGS is Grade 3, and their H/CL ratio is higher than that of the non-Ala97Ser group, but no statistical significance exists (mean H/CL: 1.95 ± 0.06 vs. 1.87 ± 0.02, p = 0.844). Additionally, ATTRv-CA patients showed VGS ≥ 2, and mean H/CL ratio of 2.09 ± 0.06. The sensitivity and specificity of VGS were 100% and 65%, respectively. And the interobserver consistency analysis of VGS showed the intraclass correlation coefficient is 0.522. The best cutoff value of H/CL ratio was 1.51 (AUC = 0.996), and the diagnostic consistency of H/CL (bias: 0.018) was high., Conclusions: Ala97Ser is the most common genotype in ATTRv-CA in our cohort, with characteristics of later onset and rapid progression, but delayed diagnosis and extensive99m Tc-PYP uptake. Overall, ATTRv-CA patients showed moderate-to-extensive myocardial99m Tc-PYP uptake. Additionally, VGS carries subjectivity, low specialty and interobserver consistency. But H/CL exhibit high diagnostic efficacy and interobserver consistency. The H/CL ratio is more useful than VGS., (© 2024. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.)- Published
- 2024
- Full Text
- View/download PDF
19. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis
- Author
-
Sarah AM Cuddy, Yesh Datar, Gavin Ovsak, Sunil Saith, Sean P. Murphy, Camden P. Bay, Mia Haddad, Brian Lilleness, Varsha Muralidhar, Alexandra Pipilas, Jacqueline Vuong, Eric Guardino, Mathew S. Maurer, Frederick L. Ruberg, Rodney H. Falk, and Sharmila Dorbala
- Subjects
Male ,Amyloid Neuropathies, Familial ,Technetium Tc 99m Pyrophosphate ,Technetium ,Diphosphates ,Echocardiography ,Humans ,Prealbumin ,Radiology, Nuclear Medicine and imaging ,Female ,Cardiology and Cardiovascular Medicine ,Cardiomyopathies ,Radionuclide Imaging ,Aged - Abstract
Background: Echocardiographic deformation-based ratios and novel multi-parametric scores have been suggested to discriminate transthyretin cardiac amyloidosis (ATTR-CM) from other causes of increased left ventricular wall thickness among patients referred for ATTR-CM evaluation. Their relative predictive accuracy has not been well studied. We sought to (1) identify echocardiographic parameters predictive of ATTR-CM and (2) compare the diagnostic accuracy of these parameters in patients with suspected ATTR-CM referred for technetium-99m-pyrophosphate scintigraphy. Methods: Echocardiograms from 598 patients referred to 3 major amyloidosis centers for technetium-99m-pyrophosphate to detect ATTR-CM were analyzed, including longitudinal strain (LS) analysis. Deformation ratios (septal apex to base ratio, relative apical sparing, ejection fraction to global LS), a multi-center European increased wall thickness score, and Mayo Clinic derived ATTR score (transthyretin cardiac amyloidosis score) were calculated. A logistic regression model was used to identify the parameters that best associated with a diagnosis of ATTR-CM. Comparison of the diagnostic capacity of the parameters was performed by receiver operating characteristic curves and the area under the curve (AUC). Results: Over half of the subjects (54.2%) were diagnosed with ATTR-CM (78% were men, median age of 76 years). Age, inferolateral wall thickness, and basal LS were the strongest predictors of ATTR-CM, AUC of 0.87 (95% CI: 0.83, 0.90), superior to the increased wall thickness score AUC of 0.78 (95% CI: 0.73, 0.83; P =0.004). An inferolateral wall thickness of ≥14 mm (AUC: 0.73) was as accurate as the published cut-offs for transthyretin cardiac amyloidosis score and septal apex to base (AUC: 0.72 and 0.69, P =0.8 and P =0.1, respectively), and was superior to ejection fraction to global LS and relative apical sparing (AUC: 0.64 and 0.53, P P =0.2); outperforming the other indices ( P Conclusion: Inferolateral wall thickness and average basal LS performed as well as or better than more complex echo ratios and multiparametric scores to predict ATTR-CM.
- Published
- 2023
20. Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging
- Author
-
Rabah Alreshq, Matthew Cozzolino, Brian Lilleness, Alexandra Pipilas, Lisa Mendelson, Tracy Joshi, Varsha Muralidhar, Eric Guardino, John L. Berk, Omar K. Siddiqi, Deepa M. Gopal, Vaishali Sanchorawala, and Frederick L. Ruberg
- Subjects
Aged, 80 and over ,Male ,Technetium Tc 99m Pyrophosphate ,Technetium ,Amyloidosis ,Diphosphates ,Humans ,Prealbumin ,Female ,Immunoglobulin Light-chain Amyloidosis ,Radiopharmaceuticals ,Cardiomyopathies ,Cardiology and Cardiovascular Medicine ,Aged ,Retrospective Studies - Abstract
Clinical algorithms stipulate that transthyretin amyloid cardiomyopathy (ATTR-CM) can be diagnosed noninvasively by technetium-99m pyrophosphate (PYP) imaging when light chain (AL) amyloidosis has been excluded. We sought to define the distribution of light chain abnormalities and final diagnosis of ATTR-CM among patients referred for PYP imaging. We conducted a retrospective cohort study of 378 sequential patients with suspected ATTR-CM, referred for PYP imaging from October 2014 to January 2019. PYP scans were adjudicated as per guidelines. We found that 97 patients (26%) had abnormal plasma cell dyscrasia (PCD) markers, including serum free light chain (FLC) and/or urine/serum immunofixation electrophoresis (IFE). After exclusions for incomplete data or known AL amyloidosis, the final study population with abnormal PCD testing was n = 82. Final adjudication of amyloidosis was determined by multidisciplinary clinical assessment and/or tissue biopsy. The median age of cohort was 75 (68 to 81) years, 88% were men, and 33% were Black. Of the 82 patients, 62 had positive PYP scans (76%) and 20 had negative PYP scans (24%). A total of 64 patients had adjudicated ATTR-CM, confirmed by tissue biopsy in 41 (64%). Of those with confirmed ATTR-CM, 44 (69%) had abnormal FLC ratio between 1.65 and 3.1 and normal IFE. In conclusion, among patients referred for technetium-99m-PYP imaging for suspected ATTR-CM, 26% exhibited abnormalities of PCD markers. An FLC ratio 1.65 to 3.1, with normal IFE was noted in 69% of those with ATTR-CM, suggesting that ATTR-CM can be diagnosed noninvasively without cardiac biopsy in patients with positive PYP scan and similar plasma cell testing results.
- Published
- 2022
- Full Text
- View/download PDF
21. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction
- Author
-
Daniel R. Davies, Margaret M. Redfield, Christopher G. Scott, Masatoshi Minamisawa, Martha Grogan, Angela Dispenzieri, Panithaya Chareonthaitawee, Amil M. Shah, Sanjiv J. Shah, Ramsey M. Wehbe, Scott D. Solomon, Yogesh N. V. Reddy, Barry A. Borlaug, and Omar F. AbouEzzeddine
- Subjects
Heart Failure ,Male ,Technetium Tc 99m Pyrophosphate ,Humans ,Prealbumin ,Female ,Stroke Volume ,Amyloidosis ,Radiopharmaceuticals ,Cardiology and Cardiovascular Medicine ,Cardiomyopathies ,Retrospective Studies - Abstract
ImportanceTransthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart failure (HF) with preserved ejection fraction (HFpEF). Technetium Tc 99m pyrophosphate scintigraphy (PYP) enables ATTR-CM diagnosis. It is unclear which patients with HFpEF have sufficient risk of ATTR-CM to warrant PYP.ObjectiveTo derive and validate a simple ATTR-CM score to predict increased risk of ATTR-CM in patients with HFpEF.Design, Setting, and ParticipantsRetrospective cohort study of 666 patients with HF (ejection fraction ≥ 40%) and suspected ATTR-CM referred for PYP at Mayo Clinic, Rochester, Minnesota, from May 10, 2013, through August 31, 2020. These data were analyzed September 2020 through December 2020. A logistic regression model predictive of ATTR-CM was derived and converted to a point-based ATTR-CM risk score. The score was further validated in a community ATTR-CM epidemiology study of older patients with HFpEF with increased left ventricular wall thickness ([WT] ≥ 12 mm) and in an external (Northwestern University, Chicago, Illinois) HFpEF cohort referred for PYP. Race was self-reported by the participants. In all cohorts, both case patients and control patients were definitively ascertained by PYP scanning and specialist evaluation.Main Outcomes and MeasuresPerformance of the derived ATTR-CM score in all cohorts (referral validation, community validation, and external validation) and prevalence of a high-risk ATTR-CM score in 4 multinational HFpEF clinical trials.ResultsParticipant cohorts included were referral derivation (n = 416; 13 participants [3%] were Black and 380 participants [94%] were White; ATTR-CM prevalence = 45%), referral validation (n = 250; 12 participants [5%]were Black and 228 participants [93%] were White; ATTR-CM prevalence = 48% ), community validation (n = 286; 5 participants [2%] were Black and 275 participants [96%] were White; ATTR-CM prevalence = 6% ), and external validation (n = 66; 23 participants [37%] were Black and 36 participants [58%] were White; ATTR-CM prevalence = 39%). Score variables included age, male sex, hypertension diagnosis, relative WT more than 0.57, posterior WT of 12 mm or more, and ejection fraction less than 60% (score range −1 to 10). Discrimination (area under the receiver operating characteristic curve [AUC] 0.89; 95% CI, 0.86-0.92; P 2 = 4.6; P = .46) were strong. Discrimination (AUC ≥ 0.84; P 2 = 2.8; P = .84; Hosmer-Lemeshow χ2 = 4.4; P = .35; Hosmer-Lemeshow χ2 = 2.5; P = .78 in referral, community, and external validation cohorts, respectively) were maintained in all validation cohorts. Precision-recall curves and predictive value vs prevalence plots indicated clinically useful classification performance for a score of 6 or more (positive predictive value ≥25%) in clinically relevant ATTR-CM prevalence (≥10% of patients with HFpEF) scenarios. In the HFpEF clinical trials, 11% to 35% of male and 0% to 6% of female patients had a high-risk (≥6) ATTR-CM score.Conclusions and RelevanceA simple 6 variable clinical score may be used to guide use of PYP and increase recognition of ATTR-CM among patients with HFpEF in the community. Further validation in larger and more diverse populations is needed.
- Published
- 2023
22. 99mTc-Pyrophosphate Scintigraphy Can Image Tracer Uptake in Skeletal Trunk Muscles of Transthyretin Cardiac Amyloidosis
- Author
-
Koji, Takahashi, Yoshiyasu, Hiratsuka, Daisuke, Sasaki, Tomoki, Sakaue, Daijiro, Enomoto, Hiroe, Morioka, Shigeki, Uemura, Takafumi, Okura, Shuntaro, Ikeda, Taizo, Kono, Takaaki, Iwamura, Nobuhisa, Yamamura, Sohei, Kitazawa, and Mitsuharu, Ueda
- Subjects
Technetium Tc 99m Pyrophosphate ,Humans ,Prealbumin ,Radiology, Nuclear Medicine and imaging ,Amyloidosis ,General Medicine ,Radiopharmaceuticals ,Cardiomyopathies ,Radionuclide Imaging ,Muscle, Skeletal - Abstract
99mTc-pyrophosphate (99mTc-PYP) uptake in the skeletal muscles is minimal in patients with transthyretin cardiac amyloidosis (ATTR-CA) when assessed qualitatively and quantitatively. We previously demonstrated moderate- to high-grade 99mTc-PYP uptake in the subcutaneous abdominal fat of some patients with ATTR-CA and showed that this abnormal finding could reflect the regional amyloid burden of this tissue. We aimed to investigate the frequency of 99mTc-PYP uptake in skeletal trunk muscles of patients with ATTR-CA.Chest- and abdomen-centered 99mTc-PYP scintigraphy images were obtained 2 hours after IV injections of the tracer (20 mCi) in 36 patients with ATTR-CA. The frequency of 99mTc-PYP uptake in the following 11 skeletal trunk muscles was investigated: pectoralis major, deltoid, subscapularis, infraspinatus, trapezius, latissimus dorsi, erector spinae, psoas major, abdominal oblique, rectus abdominis, and the gluteus muscles.Ten of the 11 muscles were involved in patients with the highest number of 99mTc-PYP uptake in the skeletal trunk muscles examined, whereas no muscle was involved in a patient with the least uptake. The muscle with the highest rate of 99mTc-PYP uptake, observed in 34 of 36 patients (94.4%), was the abdominal oblique. No tracer uptake was observed in the psoas major. The frequency of radiotracer uptake in the remaining examined muscles was between those of abdominal oblique and psoas major muscles.Radiotracer uptake was often detectable in some skeletal trunk muscles of ATTR-CA, although the muscles of patients examined and the skeletal trunk muscles of 1 patient showed heterogeneity in the uptake of 99mTc-PYP.
- Published
- 2022
- Full Text
- View/download PDF
23. Deep learning approach for automated segmentation of myocardium using bone scintigraphy single-photon emission computed tomography/computed tomography in patients with suspected cardiac amyloidosis.
- Author
-
Bhattaru A, Rojulpote C, Vidula M, Duda J, Maclean MT, Swago S, Thompson E, Gee J, Pieretti J, Drachman B, Cohen A, Dorbala S, Bravo PE, and Witschey WR
- Subjects
- Humans, Female, Single Photon Emission Computed Tomography Computed Tomography methods, Radionuclide Imaging, Technetium Tc 99m Pyrophosphate, Myocardium, Prealbumin, Amyloid Neuropathies, Familial diagnostic imaging, Deep Learning, Cardiomyopathies diagnostic imaging
- Abstract
Background: We employed deep learning to automatically detect myocardial bone-seeking uptake as a marker of transthyretin cardiac amyloid cardiomyopathy (ATTR-CM) in patients undergoing 99mTc-pyrophosphate (PYP) or hydroxydiphosphonate (HDP) single-photon emission computed tomography (SPECT)/computed tomography (CT)., Methods: We identified a primary cohort of 77 subjects at Brigham and Women's Hospital and a validation cohort of 93 consecutive patients imaged at the University of Pennsylvania who underwent SPECT/CT with PYP and HDP, respectively, for evaluation of ATTR-CM. Global heart regions of interest (ROIs) were traced on CT axial slices from the apex of the ventricle to the carina. Myocardial images were visually scored as grade 0 (no uptake), 1 (uptake
ribs). A 2D U-net architecture was used to develop whole-heart segmentations for CT scans. Uptake was determined by calculating a heart-to-blood pool (HBP) ratio between the maximal counts value of the total heart region and the maximal counts value of the most superior ROI., Results: Deep learning and ground truth segmentations were comparable (p=0.63). A total of 42 (55%) patients had abnormal myocardial uptake on visual assessment. Automated quantification of the mean HBP ratio in the primary cohort was 3.1±1.4 versus 1.4±0.2 (p<0.01) for patients with positive and negative cardiac uptake, respectively. The model had 100% accuracy in the primary cohort and 98% in the validation cohort., Conclusion: We have developed a highly accurate diagnostic tool for automatically segmenting and identifying myocardial uptake suggestive of ATTR-CM., (Copyright © 2024 American Society of Nuclear Cardiology. Published by Elsevier Inc. All rights reserved.) - Published
- 2024
- Full Text
- View/download PDF
24. Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis.
- Author
-
Takahashi K, Hiratsuka Y, Iwamura T, Sasaki D, Yamamura N, Kitazawa S, Ueda M, Morioka H, Okura T, Enomoto D, Uemura S, Kono T, Sakaue T, and Ikeda S
- Subjects
- Humans, Male, Aged, 80 and over, Female, Technetium Tc 99m Pyrophosphate, Diphosphates, Technetium, Prealbumin genetics, Abdominal Oblique Muscles, Tomography, X-Ray Computed, Biopsy, Biopsy, Needle, Radiopharmaceuticals, Amyloidosis genetics, Cardiomyopathies diagnostic imaging
- Abstract
Background: Technetium-99m-pyrophosphate (
99m Tc-PYP) uptake in the internal oblique muscle (IOM), which is often observed in patients with wild-type transthyretin cardiac amyloidosis (ATTR-CA), indicates amyloid transthyretin (ATTR) deposition., Objective: This study aimed to assess the safety and efficacy of99m Tc-PYP imaging-based computed tomography (CT)-guided core-needle biopsy of the IOM as a new extracardiac screening biopsy for confirming the presence of ATTR deposits., Methods: Patients with suspected ATTR-CA in whom myocardial tracer uptake was detected on chest- and abdomen-centered images of99m Tc-PYP scintigraphy underwent CT-guided core-needle biopsy at the site with the highest tracer uptake in the IOM between September 2021 and November 2022., Results: All 18 consecutive patients (mean age, 86.3 years ± 6.5; 61.1% male) enrolled in the study showed99m Tc-PYP uptake into the IOM. Adequate tissue samples were obtained from all patients except one without serious complications. Immunohistochemical analysis confirmed ATTR deposits in 16/18 (88.9%) patients. In the remaining two patients, ATTR deposits were observed via endomyocardial biopsy. All patients were diagnosed with wild-type ATTR-CA based on transthyretin gene sequence testing results., Conclusion: In wild-type ATTR-CA,99m Tc-PYP imaging-based CT-guided core-needle biopsy of the IOM could be used as an extracardiac screening biopsy to confirm the presence of ATTR deposits.- Published
- 2024
- Full Text
- View/download PDF
25. Inappropriate use of technetium-99m pyrophosphate scanning for the evaluation of transthyretin amyloidosis.
- Author
-
Yan CL, Thakkar Rivera N, and Hoffman J
- Subjects
- Humans, Diphosphates, Technetium, Technetium Tc 99m Pyrophosphate, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial genetics, Cardiomyopathies
- Published
- 2024
- Full Text
- View/download PDF
26. Low-sensitivity 99mTc pyrophosphate scintigraphy for hereditary transthyretin cardiac amyloidosis with Glu112Lys genotype.
- Author
-
Deng Y, Pan R, Guo Y, Wang X, and Tian Z
- Subjects
- Humans, Technetium Tc 99m Pyrophosphate, Prealbumin genetics, Radionuclide Imaging, Genotype, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial genetics, Cardiomyopathies diagnostic imaging
- Abstract
Competing Interests: Conflict of interest: None declared.
- Published
- 2024
- Full Text
- View/download PDF
27. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
- Author
-
Yamaguchi S, Oda S, Kidoh M, Hayashi H, Takashio S, Usuku H, Nagayama Y, Nakaura T, Tsujita K, Hirai T, and Aoki T
- Subjects
- Humans, Prealbumin, Technetium Tc 99m Pyrophosphate, Retrospective Studies, Stroke Volume, Ventricular Function, Left, Magnetic Resonance Imaging, Edema, Biomarkers, Cardiomyopathies diagnostic imaging, Amyloidosis diagnostic imaging
- Abstract
Rationale and Objectives: This study aimed to assess the utility of cardiac magnetic resonance imaging (MRI) T1 and T2 mapping as quantitative imaging biomarkers in transthyretin amyloid cardiomyopathy (ATTR-CM)., Materials and Methods: This study retrospectively evaluated 74 patients with confirmed wild-type ATTR-CM who underwent cardiac MRI,
99m Tc-labeled pyrophosphate (99m Tc-PYP) scintigraphy, and echocardiography. We assessed the quantitative disease parameters, for example, left ventricular ejection fraction (LVEF), and global longitudinal strain (GLS) by echocardiography, native T1, extracellular volume fraction (ECV), and native T2 value by cardiac MRI, heart-to-contralateral ratio (H/CL) by99m Tc-PYP, and high-sensitive cardiac troponin T. Myocardial native T2 of ≥50 ms was defined as myocardial edema. Correlations between the disease's quantitative parameters were evaluated, and the ECV was compared to other parameters in ATTR-CM with/without myocardial edema., Results: ECV in all patients with ATTR-CM revealed a strong correlation with native T1 (r = 0.62), a moderate correlation with hs-TnT (r = 0.59), LVEF (r = -0.48), GLS (r = 0.58), and H/CL (r = 0.48). Correlations between ECV and other quantitative parameters decreased in ATTR-CM with myocardial edema except for H/CL. Meanwhile, the correlations increased in ATTR-CM without myocardial edema., Conclusion: The presence of myocardial edema affected the interpretation of ECV assessment, although ECV can be a comprehensive imaging biomarker for ATTR-CM. ECV showed a significant correlation with various quantitative disease parameters and can be a reliable disease monitoring marker in patients with ATTR-CM when myocardial edema was excluded., Competing Interests: Declaration of Competing Interest The authors have no direct or indirect financial interest in the products used or the subject matter discussed in this manuscript., (Copyright © 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
28. Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.
- Author
-
Yu AL, Chen YC, Tsai CH, Wu YA, Su MY, Chou CH, Shun CT, Hsueh HW, Juang JJ, Lee MJ, Tseng PH, Hsu CH, Hsieh ST, Ko CL, Cheng MF, Chao CC, and Lin YH
- Subjects
- Humans, Prealbumin genetics, Prealbumin therapeutic use, Prospective Studies, Retrospective Studies, Technetium Tc 99m Pyrophosphate, Tomography, X-Ray Computed, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial drug therapy, Cardiomyopathies diagnostic imaging, Cardiomyopathies drug therapy
- Abstract
Background: Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM., Methods and Results: We retrospectively analyzed a prospective cohort from the NEURO-TTRansform trial, including patients with hATTR-CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR-CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography was conducted at baseline and during follow-up. Thirteen patients with hATTR-CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow-up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, P =0.028), whereas the control group showed no significant change (4.079 to 3.915, P =0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (-20.7% versus -3.4%, P =0.007)., Conclusions: The volumetric heart and lung ratio used to quantify technetium-99m-pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR-CM. These findings suggest the potential efficacy of eplontersen in treating hATTR-CM and highlight the value of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
- Published
- 2024
- Full Text
- View/download PDF
29. Optimizing cardiac amyloidosis assessment: utility of 1-h and 3-h 99m Tc-PYP imaging.
- Author
-
Imakhanova A, Ideguchi R, Kawano H, Maemura K, and Kudo T
- Subjects
- United States, Aged, Humans, Technetium Tc 99m Pyrophosphate, Diagnostic Imaging, Heart diagnostic imaging, Amyloidosis diagnostic imaging, Heart Failure
- Abstract
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM), characterized by the extracellular deposition of an insoluble amyloid protein in the heart, is one of the main causes of heart failure in elderly patients. In this study, our primary objective was to explore the diverse applications and temporal significance of 1-h and 3-h imaging using
99m Tc-PYP in the context of ATTR-CM. Additionally, we compared tracer kinetics in the heart and bone to comprehensively assess the diagnostic advantages and time-related considerations associated with these two incubation periods., Methods: Twenty-seven patients at Nagasaki University Hospital who underwent99m Tc-PYP planar, and SPECT cardiac imaging were classified into two groups (ATTR-CM-positive and -negative groups) based on the American Heart Association statement. Cardiac retention was assessed with both a semiquantitative visual score and a quantitative analysis. To assess bone accumulation, a ROI with an equal volume was drawn on the sternum and calculated as the bone-to-contralateral ratio (B/CL). We also evaluated correlation between heart-to-contralateral lung (H/CL) ratio and left ventricular wall thickness., Results: Among patients who underwent99m Tc-PYP imaging, the H/CL ratio was significantly higher at 1 h than at 3 h regardless of the group (from 2.20 ± 0.36 to 1.99 ± 0.35, p < 0.01 in the positive group and from 1.35 ± 0.12 to 1.19 ± 0.21, p = 0.01 in the negative group). The gap of H/CL between highest H/CL of negative case and lowest H/CL of positive case was narrower in 3 h. On the other hand, correlation between H/CL and left ventricular posterior wall thickness tends to be clearer in 3 h (p = 0.12, r = 0.30 for 1 h, p = 0.04, r = 0.39 at 3 h)., Conclusion: Our study suggests that both 1-h and 3-h incubation times for99m Tc-PYP imaging have different benefits for ATTR cardiac amyloidosis. A one-hour incubation may be preferable for differential diagnostic purposes, while a three-hour incubation may provide greater utility in evaluating disease severity., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
30. Progressive development of cardiac amyloidosis in a hereditary transthyretin gene carrier on serial Tc-99m PYP SPECT-CT.
- Author
-
Abazid RM, Davey RA, Romsa J, Florendo-Cumbermack A, and Akincioglu C
- Subjects
- Humans, Prealbumin genetics, Heart diagnostic imaging, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed, Technetium Tc 99m Pyrophosphate, Radiopharmaceuticals, Amyloidosis, Cardiomyopathies
- Published
- 2024
- Full Text
- View/download PDF
31. Case of Biopsy-Proven Wild-Type ATTR Cardiac Amyloidosis With Abnormal CMR and Negative 99m Tc-HDP and PYP Nuclear Scintigraphy.
- Author
-
Yabut J, Nadig V, Arora S, Hirsch D, and Duvall WL
- Subjects
- Humans, Biopsy, Heart, Prealbumin, Radionuclide Imaging, Radiopharmaceuticals, Technetium Tc 99m Pyrophosphate, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial diagnostic imaging, Amyloidosis diagnostic imaging, Cardiomyopathies diagnostic imaging
- Abstract
Competing Interests: Disclosures None.
- Published
- 2024
- Full Text
- View/download PDF
32. Serial Tc-99m MDP scintigraphy demonstrating increasing cardiac uptake over time in a patient with light-chain cardiac amyloidosis
- Author
-
Hua, Lin, Xinyu, Zhang, Andrew J, Einstein, and Gongshun, Tang
- Subjects
Technetium Tc 99m Pyrophosphate ,Humans ,Radiology, Nuclear Medicine and imaging ,Amyloidosis ,Radiopharmaceuticals ,Technetium Tc 99m Medronate ,Cardiomyopathies ,Radionuclide Imaging ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
33. A Guide to the Noninvasive Imaging Assessment of Cardiac Amyloidosis
- Author
-
Sanela Music, Ariana Szilagyi, and Michael Chetrit
- Subjects
Early Diagnosis ,Technetium Tc 99m Pyrophosphate ,Echocardiography ,Disease Progression ,Humans ,Magnetic Resonance Imaging, Cine ,Amyloidosis ,Radiopharmaceuticals ,Cardiomyopathies ,Prognosis ,Radionuclide Imaging ,Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
34. Extra-cardiac uptake of 99mTc-pyrophosphate scan leading to the diagnosis of stage IV metastatic prostatic adenocarcinoma.
- Author
-
Raval M and Siddiq S
- Subjects
- Humans, Technetium Tc 99m Pyrophosphate, Radionuclide Imaging, Technetium, Heart, Adenocarcinoma diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
35. Single photon emission computed tomography pyrophosphate imaging for transthyretin cardiac amyloid.
- Author
-
Hudson O and Hage FG
- Subjects
- Humans, Prealbumin, Tomography, Emission-Computed, Single-Photon methods, Heart diagnostic imaging, Technetium Tc 99m Pyrophosphate, Diphosphates, Cardiomyopathies
- Published
- 2023
- Full Text
- View/download PDF
36. Transthyretin amyloid cardiomyopathy disease burden quantified using 99m Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours.
- Author
-
Watanabe S, Nakajima K, Toshima F, Wakabayashi H, Yoshida S, Yoneyama H, Komatsu J, Konishi T, and Kinuya S
- Subjects
- Humans, Diphosphates, Technetium Tc 99m Pyrophosphate, Prealbumin genetics, Stroke Volume, Retrospective Studies, Ventricular Function, Left, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed, Radiopharmaceuticals, Cardiomyopathies genetics, Amyloidosis
- Abstract
Background: Various parameters derived from technetium-99m pyrophosphate (
99m Tc-PYP) single-photon emission computed tomography (SPECT) correlate with the severity of transthyretin amyloid cardiomyopathy (ATTR-CM). However, the optimal metrics and image acquisition timing required to quantify the disease burden remain uncertain., Methods and Results: We retrospectively evaluated99m Tc-PYP SPECT/CT images of 23 patients diagnosed with ATTR-CM using endomyocardial biopsies and/or gene tests. All patients were assessed by SPECT/CT 1 hour after99m Tc-PYP injection, and 13 of them were also assessed at 3 hours. We quantified99m Tc-PYP uptake using the volumetric parameters, cardiac PYP volume (CPV) and cardiac PYP activity (CPA). We also calculated the SUVmax ratios of myocardial SUVmax/blood pool SUVmax, myocardial SUVmax/bone SUVmax, and the SUVmax retention index. We assessed the correlations between uptake parameters and the four functional parameters associated with prognosis, namely left ventricular ejection fraction, global longitudinal strain, myocardial extracellular volume, and troponin T. CPV and CPA correlated more closely than the SUVmax ratios with the four prognostic factors. Significant correlations between volumetric parameters and prognostic factors were equivalent between 1 and 3 hours., Conclusions: The disease burden of ATTR-CM was quantified more accurately by volumetric evaluation of99m Tc-PYP SPECT/CT than SUVmax ratios and the performance was equivalent between 1 and 3 hours., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
37. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases.
- Author
-
Chan N, Einstein AJ, Griffin JM, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson LL, Kinkhabwala MP, Leb JS, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith SE, Winburn M, Smiley D, Miller EJ, Ruberg FL, and Maurer MS
- Subjects
- Male, Humans, Aged, Middle Aged, Female, Diphosphates, Technetium, Technetium Tc 99m Pyrophosphate, Prevalence, Tomography, X-Ray Computed, Radiopharmaceuticals, Prealbumin, Cardiomyopathies, Amyloidosis
- Abstract
Introduction: Technetium-labeled bone-avid radiotracers can be used to diagnose transthyretin cardiac amyloidosis (ATTR-CA). Extracardiac uptake of technetium pyrophosphate (Tc-99m PYP) in this context has not been extensively explored and its significance is not well characterized. We assessed extracardiac Tc-99m PYP uptake in individuals undergoing nuclear scintigraphy and the extent of clinically actionable findings., Methods: The Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations (SCAN-MP) study utilizes Tc-99m PYP imaging to identify ATTR-CA in self-identified Black and Caribbean Hispanic participants ≥ 60 years old with heart failure. We characterized the distribution of extracardiac uptake, including stratification of findings by timing of scan (1 hour vs 3 hours after Tc-99m PYP administration) and noted any additional testing in these subjects., Results: Of 379 participants, 195 (51%) were male, 306 (81%) Black race, and 120 (32%) Hispanic ethnicity; mean age was 73 years. Extracardiac Tc-99m PYP uptake was found in 42 subjects (11.1%): 21 with renal uptake only, 14 with bone uptake only, 4 with both renal and bone uptake, 2 with breast uptake, and 1 with thyroid uptake. Extracardiac uptake was more common in subjects with Tc-99m PYP scans at 1 hour (23.8%) than at 3 hours (6.2%). Overall, four individuals (1.1%) had clinically actionable findings., Conclusion: Extracardiac Tc-99m PYP uptake manifested in about 1 in 9 SCAN-MP subjects but was clinically actionable in only 1.1% of cases., (© 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
38. Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study.
- Author
-
Akincioglu C, Murthi M, Romsa J, Warrington J, and Malhotra S
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Diphosphates, Prealbumin, Radionuclide Imaging, Technetium, Technetium Tc 99m Pyrophosphate, Quality Assurance, Health Care, Amyloidosis diagnostic imaging, Cardiomyopathies diagnostic imaging
- Abstract
Background: SPECT improves diagnostic specificity of Technetium-99m pyrophosphate (PYP) scintigraphy. Diagnostic performance of PYP data, reconstructed as either chest or cardio-focal SPECT is not known., Methods: In this quality assurance study, blinded evaluation of PYP SPECT/CT data from 102 Caucasian patients (mean age 76 ± 11 years, 67% men) was performed by two readers. Reader 1 reviewed planar and PYP chest SPECT, while reader 2 reviewed planar and cardio-focal PYP SPECT. Demographic, clinical, and other testing data were obtained from the electronic medical records., Results: A total of 41 patients (40%) were considered positive based on myocardial uptake on chest PYP SPECT. Of these, 98% of the patients had a Perugini score ≥ 2 on planar imaging. There was good agreement between the two readers for visual score ≥ 2 (k = .88, P < .001) and excellent agreement for myocardial uptake on tomographic imaging (98%, P < .001). Only one study was categorized as false negative by cardio-focal SPECT reconstruction. Non-diffuse myocardial uptake was identified in 22% of those with a positive PYP SPECT., Conclusion: When read by experienced readers, chest and cardio-focal reconstruction of PYP SPECT have comparable diagnostic performance. A substantial proportion of patients with a positive PYP SPECT have a non-diffuse distribution of PYP. Given the possibility of misclassification of non-diffuse myocardial uptake on cardio-focal reconstruction alone, chest reconstruction of PYP scintigraphy should be strongly considered., (© 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
39. Improving evaluation for TTR amyloidosis by interactive filtering of Tc-99 m PYP SPECT images. The role for "clean blood pool" imaging.
- Author
-
Hansen CL
- Subjects
- Humans, Technetium Tc 99m Pyrophosphate, Prealbumin, Heart, Tomography, Emission-Computed, Single-Photon, Radiopharmaceuticals, Amyloidosis, Cardiomyopathies
- Abstract
Background: Myocardial imaging with bone agents such as Tc-99 m PYP and HMDP has assumed a central role in the evaluation of patients with suspected transthyretin (TTR) amyloidosis. Visual scoring (VS) (0-3 +) and the heart to contralateral lung ratio (HCL) classify many patients as equivocal when mediastinal uptake is apparent but cannot be further differentiated into myocardial uptake versus blood pool. SPECT imaging has been recommended but current reconstruction protocols frequently produce amorphous mediastinal activity that also fails to discriminate between myocardial activity and blood pool. We hypothesized that interactive filtering interactively using a deconvolving filter would improve this., Methods: We identified 176 sequential patients referred for TTR amyloid imaging. All patients had planar imaging, 101 had planar imaging with a large field of view camera that allowed HCL measurements. SPECT imaging was performed on a 3-headed digital camera with lead fluorescence attenuation correction. One study was excluded for technical reasons. We created software to allow interactive filtering while reconstructing the images then overlay them on attenuation mu maps to assist localization of myocardial/mediastinal uptake. Conventional Butterworth and an interactive inverse Gaussian filters were employed to differentiate myocardial uptake from residual blood pool. We defined "clean blood pool" (CBP) as recognizable blood pool with no activity in the surrounding myocardium. A scan was determined diagnostic if it showed CBP, positive uptake or no identifiable mediastinal uptake., Results: 76/175 (43%) were equivocal (1 +) by visual uptake. Of these 22 (29%) were diagnostic by Butterworth but 71 (93%) were by inverse gaussian (p < .0001). 71/101 (70%) were equivocal by HCL (1-1.5). Of these, 25 (35%) were diagnostic by Butterworth but 68 (96%) were diagnostic by inverse gaussian (p < .0001). This was driven by a greater than threefold increase in the identification of CBP by inverse gaussian filtering., Conclusion: CBP can be identified in the vast majority of patients with equivocal PYP scans using optimized reconstruction and can greatly reduce the number of equivocal scans., (© 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
40. Extra-cardiac uptake on technetium-99m pyrophosphate (Tc-99m PYP) scan: not just a matter of the heart.
- Author
-
Khor YM and Dorbala S
- Subjects
- Humans, Technetium, Technetium Tc 99m Pyrophosphate, Heart diagnostic imaging, Radionuclide Imaging, Diphosphates, Cardiomyopathies diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
41. Hyperphosphatemia-Related False-Positive 99m Tc-Pyrophosphate Myocardial Scan: A Case Report With Endomyocardial Biopsy Result.
- Author
-
Hu LH, Kuo Y, Chang FP, Wang WT, Yang BH, Huang WS, and Wang YF
- Subjects
- Humans, Diphosphates, Prealbumin, Technetium Tc 99m Pyrophosphate, Technetium, Biopsy, Hyperphosphatemia diagnostic imaging, Cardiomyopathies diagnostic imaging
- Abstract
Abstract: With documented high specificity, 99m Tc-pyrophosphate (PYP) scan enables the diagnosis of transthyretin cardiomyopathy to be made reliably without endomyocardial biopsy in patients who do not have monoclonal gammopathy. We report a case with extensive myocardial uptake of Perugini 3 score in the 3-hour 99m Tc-PYP myocardial SPECT that suggested transthyretin cardiac amyloidosis. However, a followed endomyocardial biopsy revealed no amyloid deposition. In this case, hyperphosphatemia was the most likely and presumptive cause of the false-positive 99m Tc-PYP scan. With this case, our experiences of the potential causes of false-positive results of 99m Tc-PYP are further expanded., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
42. Two autopsy cases of wild-type transthyretin cardiac amyloidosis who died 10 days after technetium-99m-pyrophosphate scintigraphy.
- Author
-
Takahashi K, Morioka H, Sasaki D, Yamamura N, Kitazawa S, Ueda M, Sakaue T, Enomoto D, Uemura S, Okura T, and Ikeda S
- Subjects
- Humans, Diphosphates, Technetium, Prealbumin, Technetium Tc 99m Pyrophosphate, Radionuclide Imaging, Autopsy, Radiopharmaceuticals, Amyloidosis diagnostic imaging, Cardiomyopathies diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
43. 99m Tc-PYP SPECT/CT as part of the diagnostic workup of left ventricular apical aneurysm in a patient with hypertrophic cardiomyopathy.
- Author
-
Takahashi K, Sasaki D, Uemura S, Okura T, Yamamura N, Hijiyama T, Seike S, Sakaue T, and Ikeda S
- Subjects
- Humans, Technetium Tc 99m Pyrophosphate, Single Photon Emission Computed Tomography Computed Tomography, Cardiomyopathy, Hypertrophic complications, Cardiomyopathy, Hypertrophic diagnostic imaging, Heart Aneurysm complications, Heart Aneurysm diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
44. Use of SPECT imaging to confirm ATTR cardiac amyloid in a Tc99m pyrophosphate study artefactually compromised by a recent V/Q scan.
- Author
-
Sutherland N, Sivaratnam D, Pearson M, and Better N
- Subjects
- Humans, Technetium Tc 99m Pyrophosphate, Tomography, Emission-Computed, Single-Photon, Heart, Prealbumin, Diphosphates, Cardiomyopathies
- Published
- 2023
- Full Text
- View/download PDF
45. A case of disappearing amyloid on technetium pyrophosphate scan.
- Author
-
Wang A, Mahmood U, Tang X, Jain D, and Pan S
- Subjects
- Humans, Diphosphates, Technetium, Technetium Tc 99m Pyrophosphate, Prealbumin, Radionuclide Imaging, Radiopharmaceuticals, Cardiomyopathies diagnostic imaging, Amyloidosis diagnostic imaging
- Abstract
Technetium-99mm pyrophosphate (Tc-PYP) scintigraphy is a highly accurate non-invasive method for the diagnosis of transthyretin (ATTR) cardiac amyloidosis. Prognosis for this disease is improved following treatment with the transthyretin (TTR) stabilizer tafamidis. Although tafamidis slows disease progression, its effects on myocardial amyloid and Tc-PYP uptake remain unclear. We present a patient with ATTR cardiac amyloidosis who had a strongly positive initial Tc-PYP scan, with a dramatic decrease in Tc-PYP uptake on repeat scan after 3 years of tafamidis treatment. However, myocardial biopsy showed persistent diffuse amyloid deposits. This case highlights the need for further studies regarding the utility of serial Tc-PYP scans in monitoring the progress of ATTR cardiomyopathy., (© 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
46. Response by Hussain et al to Letter Regarding Article, 'Association Between Atrial Uptake on Cardiac Scintigraphy With Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers and Atrial Fibrillation'
- Author
-
Muzna Hussain, Alison Krywanczyk, Eoin Donnellan, Trejeeve Martyn, Ossama Abou Hassan, Saqer Alkharabsheh, Chris Watson, W. H. Tang, Deborah Kwon, Paul Cremer, Feixiong Cheng, Mohamed Kanj, Brian Griffin, Carmela Tan, E. Rene Rodriguez, Mazen Hanna, Wael Jaber, and Patrick Collier
- Subjects
Diphosphates ,Technetium Tc 99m Pyrophosphate ,Atrial Fibrillation ,Humans ,Technetium ,Radiology, Nuclear Medicine and imaging ,Cardiology and Cardiovascular Medicine ,Radionuclide Imaging - Published
- 2022
47. Quantitative SPECT in PYP imaging: Ready for prime time or too early to tell?
- Author
-
Shivda, Pandey
- Subjects
Tomography, Emission-Computed, Single-Photon ,Technetium Tc 99m Pyrophosphate ,Humans ,Radiology, Nuclear Medicine and imaging ,Cardiology and Cardiovascular Medicine - Published
- 2021
- Full Text
- View/download PDF
48. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis
- Author
-
Robert J.H. Miller, Darren Mah, Nowell M. Fine, Sebastien Cadet, Denise Chan, Piotr J. Slomka, Payam Pournazari, and Daniel S. Berman
- Subjects
Male ,Technetium Tc 99m Pyrophosphate ,030204 cardiovascular system & hematology ,Article ,Ventricular Function, Left ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Clinical significance ,Aged ,Retrospective Studies ,Aged, 80 and over ,Observer Variation ,Tomography, Emission-Computed, Single-Photon ,Amyloid Neuropathies, Familial ,Ejection fraction ,biology ,Receiver operating characteristic ,business.industry ,Hazard ratio ,Stroke Volume ,Middle Aged ,Prognosis ,medicine.disease ,Diphosphates ,Transthyretin ,ROC Curve ,Cardiac amyloidosis ,Heart failure ,biology.protein ,Female ,Radiopharmaceuticals ,Cardiomyopathies ,Cardiology and Cardiovascular Medicine ,Nuclear medicine ,business ,Technetium-99m - Abstract
Patients who underwentQuantitative assessment of myocardial radiotracer activity with CPA or VOI have high diagnostic accuracy for ATTR-CM. Both measures are potential non-invasive markers to follow progression of disease or response to therapy.Las imágenes deLa evaluación cuantitativa de la actividad del radiotrazador en miocárdico con CPA o VOI tiene una alta certeza diagnóstica para ATTR-CM. Ambas medidas son potenciales marcadores no invasivos para seguir la progresión de la enfermedad o la respuesta a terapia.背景:L’imagerie au 99mTc-pyrophosphate est devenue une méthode non invasive importante pour le diagnostic de l’amyloidose cardiaque à transthyrétine (ATTR-CM). La quantification de l’activité du 99mTc-pyrophosphate sur les images SPECT, pourrait être un marqueur de l’intensité de la maladie. Dans cette étude, nous avons évalué la précision diagnostique et la signification clinique de la quantification au 99mTc-pyrophosphate. MéTHODES ET RéSULTATS: Les patients ayant bénéficié d’une imagerie au 99mTc-pyrophosphate pour suspicion d’ATTR-CM ont été inclus. Nous avons calculé l’activité (CPA) et le volume (VOI) du 99mTc-pyrophosphate (CPA) au niveau du myocarde sur les images SPECT en rapport à l’activité sanguine au niveau de la cavité ventriculaire gauche. La précision du test a été évaluée en utilisant la surface (AUC) sous la courbe ROC. Au total, 124 patients ont été étudiés (âge moyen de 73,9 ± 11,4). Quarante trois de ces patients (34.7%) furent diagnostiqués positivement pour l’ ATTR-CM. La précision diagnostique de la CPA s’est révélée la plus élevée (AUC 0,996, IC à 95% 0,987 - 1,00), et s’est avérée significativement plus élevée que le score de Perugini (AUC 0,952, p = 0,016). Chez les patients avec ATTR-CM, la CPA est associée à une fraction d’éjection ventriculaire gauche réduite (odds ratio ajusté de 1,28, p = 0,035) et une augmentation d’ hospitalisation pour insuffisance cardiaque (hazard ratio ajusté de 1,29, p = 0,006).L’évaluation quantitative de l’activité du 99mTc-pyrophosphate est d’une grande précision diagnostique pour l’ ATTR-CM. Les mesures CAP et VOI sont des marqueurs non invasifs potentiels pour le suivi de la progression de la maladie ou réponse au traitement.
- Published
- 2021
- Full Text
- View/download PDF
49. Radiopharmaceutical supply disruptions and the use ofsup99m/supTc-hydroxymethylene diphosphonate as an alternative tosup99m/supTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement
- Author
-
Edward J, Miller, Roxana, Campisi, Nishant R, Shah, Sean, McMahon, Sarah, Cuddy, Cesia, Gallegos-Kattan, Mathew S, Maurer, Thibaud, Damy, Riemer H J A, Slart, Ketan, Bhatia, and Andrew J, Einstein
- Subjects
Diphosphates ,Technetium Tc 99m Pyrophosphate ,Diphosphonates ,Humans ,Prealbumin ,Amyloidosis ,Radiopharmaceuticals ,Cardiomyopathies - Published
- 2022
50. [Myocardial scintigraphy with
- Author
-
A A, Ansheles, S N, Nasonova, I V, Zhirov, M A, Saidova, O V, Stukalova, S N, Tereshchenko, and V B, Sergienko
- Subjects
Diphosphates ,Technetium Tc 99m Pyrophosphate ,Myocardial Perfusion Imaging ,Humans ,Amyloidosis ,Cardiomyopathies ,Radionuclide Imaging ,Algorithms - Abstract
The article summarizes the current experience of the nuclear medicine department of the Chazov National Medical Research Center of Cardiology in the implementation of myocardium scintigraphy with 99mTc-pyrophosphate with the differential diagnosis of the types of cardiac amyloidosis. Causes of false-positive, equivocal and non-diagnostic results, are analyzed. Possible ways to eliminate mistakes, including by modifying protocols of planar and tomographic research and optimizing the whole diagnostic algorithm for amyloidosis of the heart, are discussed.В статье суммируется текущий опыт отдела радионуклидной диагностики и позитронно-эмиссионной томографии ФГБУ НМИЦ кардиологии им. акад. Е.И. Чазова в выполнении сцинтиграфии миокарда с 99mTc-пирофосфатом при дифференциальной диагностике типов амилоидоза сердца. Проанализированы возможные причины ложноположительных, сомнительных и недиагностических результатов исследования, предложены способы их устранения, в том числе путем модификации протоколов планарного и томографического исследований и оптимизации диагностического алгоритма амилоидоза сердца в целом.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.